

# *In Vitro* Susceptibility of Adefovir-Associated H<sub>2</sub>N Mutations to other Antiviral Agents

Antiviral Therapy

12, 355-362

DOI: [10.1177/135965350701200309](https://doi.org/10.1177/135965350701200309)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 827-832.	1.3	33
2	How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting. <i>Liver Transplantation</i> , 2008, 14, S8-S14.	1.3	20
3	The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. <i>Hepatology</i> , 2008, 48, 88-98.	3.6	504
4	Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis. <i>Liver International</i> , 2008, 28, 814-820.	1.9	32
5	New paradigms for the treatment of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1182-1192.	1.4	23
6	Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. <i>Journal of Hepatology</i> , 2008, 48, 391-398.	1.8	128
7	Potency of tenofovir in chronic hepatitis B: Mono or combination therapy?. <i>Journal of Hepatology</i> , 2008, 48, 383-386.	1.8	28
8	Lamivudine-resistant chronic hepatitis B: An observational study on adefovir in monotherapy or in combination with lamivudine. <i>Journal of Hepatology</i> , 2008, 48, 540-547.	1.8	45
9	Hepatitis B: Reflections on the current approach to antiviral therapy. <i>Journal of Hepatology</i> , 2008, 48, S2-S19.	1.8	142
10	Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. <i>Journal of Hepatology</i> , 2008, 48, 747-755.	1.8	180
11	Does the presence of adefovir-resistant variants lead to failure of tenofovir monotherapy?. <i>Journal of Hepatology</i> , 2008, 49, 862-863.	1.8	4
12	Therapy of chronic hepatitis B: trends and developments. <i>Current Opinion in Pharmacology</i> , 2008, 8, 532-540.	1.7	24
13	Emerging antiviral drugs. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 393-416.	1.0	40
14	Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vector. <i>Journal of General Virology</i> , 2008, 89, 1819-1828.	1.3	41
15	Entecavir Therapy Induces de Novo HIV Reverse Transcriptase M184V Mutation in an Antiretroviral Therapy-Naive Patient. <i>Clinical Infectious Diseases</i> , 2008, 46, e88-e91.	2.9	10
16	Antiviral Effects of Lamivudine, Emtricitabine, Adefovir Dipivoxil, and Tenofovir Disoproxil Fumarate Administered Orally Alone and in Combination to Woodchucks with Chronic Woodchuck Hepatitis Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3617-3632.	1.4	33
17	Tenofovir and its potential in the treatment of hepatitis B virus. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 177.	0.9	9
18	Tenofovir: A new option for the treatment of chronic hepatitis B. <i>Virus Adaptation and Treatment</i> , 0, Volume 1, 5-10.	1.5	3

#	ARTICLE	IF	CITATIONS
19	New approaches in the management of chronic hepatitis B: role of tenofovir. <i>Infection and Drug Resistance</i> , 2009, 2, 13.	1.1	4
20	Anti-Hepatitis B Virus Activity in Vitro of Combinations of Tenofovir with Nucleoside/nucleotide Analogues. <i>Antiviral Chemistry and Chemotherapy</i> , 2009, 19, 165-176.	0.3	23
21	Tenofovir for the Treatment of Hepatitis B Virus. <i>Pharmacotherapy</i> , 2009, 29, 1212-1227.	1.2	35
22	Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. <i>Antiviral Research</i> , 2009, 81, 147-155.	1.9	53
23	Complex dynamics of hepatitis B virus resistance to adefovir. <i>Hepatology</i> , 2009, 49, 50-59.	3.6	28
24	Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. <i>Hepatology</i> , 2009, 49, 1503-1514.	3.6	710
25	Antiviral resistance and hepatitis B therapy. <i>Hepatology</i> , 2009, 49, S174-S184.	3.6	189
26	Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectives. <i>Medicinal Research Reviews</i> , 2009, 29, 611-645.	5.0	77
27	On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks. <i>Journal of Viral Hepatitis</i> , 2009, 16, 113-120.	1.0	16
28	Management and prevention of drug resistance in chronic hepatitis B. <i>Liver International</i> , 2009, 29, 108-115.	1.9	34
29	Nonpolar Nucleoside Mimics as Active Substrates for Human Thymidine Kinases. <i>Journal of the American Chemical Society</i> , 2009, 131, 5488-5494.	6.6	23
30	Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. <i>Journal of Hepatology</i> , 2009, 50, 674-683.	1.8	41
31	Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome. <i>Journal of Hepatology</i> , 2009, 51, 647-654.	1.8	23
32	Tenofovir Disoproxil Fumarate. <i>Drugs</i> , 2009, 69, 2245-2256.	4.9	25
33	Chronic hepatitis B: who to treat and which choice of treatment?. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 281-291.	2.0	9
34	Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. <i>Antiviral Therapy</i> , 2009, 14, 985-993.	0.6	24
35	Fitness and infectivity of drug-resistant and cross-resistant hepatitis B virus mutants: why and how is it studied?. <i>Antiviral Therapy</i> , 2010, 15, 521-527.	0.6	15
36	Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. <i>Hepatology</i> , 2010, 51, 73-80.	3.6	303

#	ARTICLE	IF	CITATIONS
37	Drug Therapy: Tenofovir. <i>Hepatology</i> , 2010, 52, 743-747.	3.6	18
38	Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. <i>Liver International</i> , 2010, 30, 657-668.	1.9	7
40	Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. <i>Viruses</i> , 2010, 2, 2696-2739.	1.5	35
41	Antiviral effect of entecavir in chronic hepatitis B: Influence of prior exposure to nucleos(t)ide analogues. <i>Journal of Hepatology</i> , 2010, 52, 493-500.	1.8	103
42	Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. <i>Journal of Hepatology</i> , 2010, 53, 449-454.	1.8	45
43	Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 1079-1092.	2.0	15
44	Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. <i>Gut</i> , 2011, 60, 247-254.	6.1	168
45	Variable influence of mutational patterns in reverse-transcriptase domain on replication capacity of hepatitis B virus isolates from antiviral-experienced patients. <i>Clinica Chimica Acta</i> , 2011, 412, 305-313.	0.5	12
46	Entecavir plus Adefovir Combination Treatment for Chronic Hepatitis B Patients after Failure of Nucleoside/Nucleotide Analogues. <i>Antiviral Therapy</i> , 2012, 17, 53-60.	0.6	21
47	The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adefovir. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 767-774.	1.9	11
48	Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 972-981.	1.9	15
49	Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern. <i>Journal of Viral Hepatitis</i> , 2011, 18, 206-215.	1.0	42
50	Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection. <i>Journal of Viral Hepatitis</i> , 2011, 18, e29-39.	1.0	52
51	HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A and H and its use in antiviral phenotyping assays. <i>Journal of Virological Methods</i> , 2011, 173, 340-346.	1.0	22
52	Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-Year prospective study. <i>Virology Journal</i> , 2011, 8, 444.	1.4	7
53	The main Hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication. <i>Antiviral Research</i> , 2011, 92, 271-276.	1.9	75
54	Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. <i>Current Hepatitis Reports</i> , 2011, 10, 235-243.	0.3	25
55	Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients. <i>Journal of Medical Virology</i> , 2011, 83, 953-961.	2.5	13

#	ARTICLE	IF	CITATIONS
56	No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. <i>Hepatology</i> , 2011, 53, 763-773.	3.6	163
57	Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response. <i>Hepatology</i> , 2011, 54, 443-451.	3.6	150
58	Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2715-2725.	1.3	168
59	The YMDD and rtA194T Mutations Result in Decreased Replication Capacity in Wild-Type HBV as well as in HBV with Precore and Basal Core Promoter Mutations. <i>Antiviral Chemistry and Chemotherapy</i> , 2011, 22, 13-22.	0.3	13
60	High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B. <i>The Korean Journal of Hepatology</i> , 2012, 18, 75.	1.5	13
61	Randomized Trial of Entecavir plus Adefovir in Patients with Lamivudine-Resistant Chronic Hepatitis B Who Show Suboptimal Response to Lamivudine plus Adefovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2941-2947.	1.4	26
62	Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants. <i>Antiviral Therapy</i> , 2012, 17, 701-709.	0.6	11
63	Evolution of Adefovir-Resistant HBV Polymerase Gene Variants after Switching to Tenofovir Disoproxil Fumarate Monotherapy. <i>Antiviral Therapy</i> , 2012, 17, 1049-1058.	0.6	15
64	Novel Nucleoside Analogue Fnc is Effective against Both Wild-Type and Lamivudine-Resistant HBV Clinical Isolates. <i>Antiviral Therapy</i> , 2012, 17, 1593-1599.	0.6	21
65	Rescue Therapy for Lamivudine-resistant Chronic Hepatitis B: Adefovir Monotherapy, Adefovir Plus Lamivudine or Entecavir Combination Therapy. <i>Internal Medicine</i> , 2012, 51, 1509-1515.	0.3	21
66	Prevention and management of drug resistant hepatitis B virus infections. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1432-1440.	1.4	12
67	Selection of chronic hepatitis B therapy with high barrier to resistance. <i>Lancet Infectious Diseases</i> , 2012, 12, 341-353.	4.6	127
68	Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants. <i>Journal of Hepatology</i> , 2012, 56, 1269-1275.	1.8	14
69	Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection. <i>Journal of Clinical Virology</i> , 2012, 53, 130-134.	1.6	16
70	Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 413-421.	1.4	10
71	Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. <i>Hepatology International</i> , 2012, 6, 696-706.	1.9	7
72	Tenofovir plus entecavir as rescue therapy for multidrug-resistant chronic hepatitis B. <i>Liver International</i> , 2012, 32, 171-172.	1.9	4
73	Prevalence, virology and antiviral drugs susceptibility of hepatitis B virus rtN238H polymerase mutation from 1865 Chinese patients with chronic hepatitis B. <i>Antiviral Research</i> , 2012, 93, 185-190.	1.9	13

#	ARTICLE	IF	CITATIONS
74	Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B. <i>Journal of Medical Virology</i> , 2012, 84, 18-25.	2.5	12
75	Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance. <i>Journal of Medical Virology</i> , 2012, 84, 424-430.	2.5	16
76	High Dose Lamivudine in HBV-Related Cirrhotic Patients with Unsatisfactory Response After Adefovir Add-On. <i>Digestive Diseases and Sciences</i> , 2012, 57, 561-567.	1.1	2
77	Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a "real-world" clinical practice setting in China. <i>Journal of Viral Hepatitis</i> , 2013, 20, 811-820.	1.0	15
78	Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B mono-infection. <i>Hepatology International</i> , 2013, 7, 327-334.	1.9	3
79	Molecular virology of chronic hepatitis B and C: Parallels, contrasts and impact on drug development and treatment outcome. <i>Antiviral Research</i> , 2013, 99, 34-48.	1.9	7
80	Severe acute hepatitis B in a treatment-naïve patient with antiviral drug resistant mutations in the polymerase gene. <i>Journal of Medical Virology</i> , 2013, 85, 210-213.	2.5	6
81	The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir. <i>Antiviral Research</i> , 2013, 97, 93-100.	1.9	44
82	Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen. <i>Journal of Viral Hepatitis</i> , 2013, 20, 131-140.	1.0	23
83	Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains. <i>Journal of Viral Hepatitis</i> , 2013, 20, 141-148.	1.0	9
84	Randomized Trial of the Virologic Response during up to Two Years of Entecavir-Adefovir Combination Therapy in Multiple-Drug-Refractory Chronic Hepatitis B Virus Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3369-3374.	1.4	10
85	Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir. <i>Drug Design, Development and Therapy</i> , 2014, 8, 869.	2.0	9
86	Selected Phenotypic Assays Used to Evaluate Antiviral Resistance and Viral Fitness of Hepatitis B Virus and Its Variants. <i>Intervirology</i> , 2014, 57, 225-231.	1.2	7
87	Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B. <i>Antiviral Research</i> , 2014, 112, 8-17.	1.9	3
88	Amino acid polymorphism in the reverse transcriptase region of hepatitis B virus and the relationship with nucleos(t)ide analogues treatment for preventing mother-to-infant transmission. <i>Journal of Medical Virology</i> , 2014, 86, 1288-1295.	2.5	6
89	Comparison of Lamivudine Plus Adefovir Therapy Versus Entecavir With or Without Adefovir Therapy for Adefovir-resistant Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 889-895.	1.1	8
90	Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance. <i>Current Opinion in Virology</i> , 2014, 8, 1-9.	2.6	131
91	De novo combination therapy adefovir plus lamivudine as a treatment for women of childbearing age with HBsAg-positive chronic hepatitis B Before Pregnancy. <i>Journal of Medical Virology</i> , 2014, 86, 433-436.	2.5	3

#	ARTICLE	IF	CITATIONS
92	Long-Term Efficacy of Entecavir Plus Adefovir Combination Therapy versus Entecavir Monotherapy in Adefovir Refractory Chronic Hepatitis B Patients with Prior Lamivudine Resistance. <i>Intervirolgy</i> , 2014, 57, 8-16.	1.2	8
93	<scp>HBV</scp> clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D. <i>Liver International</i> , 2014, 34, 1025-1032.	1.9	13
94	An HBV-HIV Co-infected Patient Treated with Tenofovir-based Therapy who Achieved HBs Antigen/Antibody Seroconversion. <i>Internal Medicine</i> , 2014, 53, 1343-1346.	0.3	0
95	Screening and identification of a novel adefovir dipivoxil-resistance-associated mutation rtN236V of HBV from a large cohort of HBV-infected patients. <i>Antiviral Therapy</i> , 2014, 19, 551-558.	0.6	11
96	Efficacy of tenofovir in adefovir-experienced patients compared to treatment-naïve patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2014, 19, 543-550.	0.6	11
97	Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance. <i>Journal of Medical Virology</i> , 2015, 87, 1532-1538.	2.5	10
98	Prevalence and types of drug-resistant variants in Chinese patients with acute hepatitis B. <i>Journal of Medical Virology</i> , 2015, 87, 1527-1531.	2.5	3
99	Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus. <i>Liver International</i> , 2015, 35, 2265-2274.	1.9	2
100	Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures. <i>Journal of Medical Virology</i> , 2015, 87, 1013-1021.	2.5	4
101	Stable Human Hepatoma Cell Lines for Efficient Regulated Expression of Nucleoside/Nucleotide Analog Resistant and Vaccine Escape Hepatitis B Virus Variants and Woolly Monkey Hepatitis B Virus. <i>PLoS ONE</i> , 2015, 10, e0145746.	1.1	5
103	Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination. <i>Clinical Therapeutics</i> , 2015, 37, 1433-1442.	1.1	7
104	Safety and efficacy of entecavir in adefovir-experienced patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 43-50.	1.4	7
105	Tenofovir disoproxil fumarate <i>vs</i> adefovir dipivoxil in <scp>C</scp>hinese patients with chronic hepatitis <scp>B</scp> after 48 weeks: a randomized controlled trial. <i>Journal of Viral Hepatitis</i> , 2015, 22, 85-93.	1.0	33
106	Monotherapy for hepatitis B infection: a review of treatment options. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1457-1468.	2.0	7
107	The rt<scp>A</scp>181<scp>S</scp> mutation of hepatitis <scp>B</scp> virus primarily confers resistance to adefovir dipivoxil. <i>Journal of Viral Hepatitis</i> , 2015, 22, 328-334.	1.0	23
108	Hepatitis B Virus. , 2016, , 713-770.		2
109	KASL clinical practice guidelines: management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 18-75.	4.5	155
110	Possible Involvement of Multidrug-Resistant Hepatitis B Virus sW172* Truncation Variant in the ER Stress Signaling Pathway during Hepatocarcinogenesis. <i>Japanese Journal of Infectious Diseases</i> , 2016, 69, 306-313.	0.5	1



#	ARTICLE	IF	CITATIONS
111	Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study. <i>Liver International</i> , 2016, 36, 1108-1115.	1.9	20
112	Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 241-247.	1.4	7
113	Profile of HBV polymerase gene mutations during entecavir treatment in patients with chronic hepatitis B. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 590-596.	0.7	2
114	A novel method for nucleos(t)ide analogues susceptibility assay of hepatitis B virus by viral polymerase transcomplementation. <i>Antiviral Research</i> , 2016, 126, 99-107.	1.9	1
115	Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. <i>Gut</i> , 2016, 65, 1042-1051.	6.1	76
116	Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy. <i>Liver International</i> , 2017, 37, 827-835.	1.9	13
117	Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial. <i>Hepatology</i> , 2017, 66, 772-783.	3.6	37
118	Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adevovir combination treatment. <i>Antiviral Research</i> , 2017, 143, 62-68.	1.9	6
119	Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro. <i>Antiviral Research</i> , 2017, 139, 25-31.	1.9	28
120	Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs. <i>Journal of Gastroenterology</i> , 2017, 52, 641-651.	2.3	15
121	Efficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues. <i>Chinese Medical Journal</i> , 2017, 130, 914-919.	0.9	7
122	New Antiretrovirals for HIV and Antivirals for HBV. , 2017, , 628-664.		1
123	Management of Antiviral Resistance in Chronic Hepatitis B. <i>Gut and Liver</i> , 2017, 11, 189-195.	1.4	39
124	Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 66-73.	4.5	13
125	Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 201-209.	1.1	28
126	Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation. <i>Antiviral Research</i> , 2018, 154, 26-34.	1.9	13
127	<i>Molecular Virology and Life Cycle</i> . , 2018, , 1-23.		1
128	Evolution of drug-resistant mutations in HBV genomes in patients with treatment failure during the past seven years (2010-2016). <i>Virus Genes</i> , 2018, 54, 41-47.	0.7	10



#	ARTICLE	IF	CITATIONS
129	Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients?. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-9.	0.7	1
130	Discovery of the Novel Entecavir-Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis. <i>Hepatology Communications</i> , 2018, 2, 1123-1135.	2.0	2
131	RIG-I Enhances Interferon- $\alpha$ Response by Promoting Antiviral Protein Expression in Patients with Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2018, 23, 575-583.	0.6	7
132	KASL clinical practice guidelines for management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 93-159.	4.5	171
133	Pharmacokinetics and Pharmacodynamics of Antiviral Drugs in Special Population. , 2019, , 977-1001.		0
134	&lt;p&gt;Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications&lt;/p&gt;. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 977-987.	1.1	5
135	Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial. <i>Journal of Hepatology</i> , 2019, 71, 35-44.	1.8	29
136	Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019, 70, 1093-1102.	1.8	107
137	Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update. <i>Hepatology Research</i> , 2020, 50, 892-923.	1.8	66
138	Differential Effectiveness of Tenofovir and Entecavir for Prophylaxis of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Depending on Coexisting Cirrhosis and Prior Exposure to Antiviral Therapy. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, e77-e86.	1.1	7
139	Tenofovir disoproxil fumarate on the risk of hepatocellular carcinoma in chronic hepatitis B patients with failure to preceding treatments: A nationwide cohort study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1150-1159.	1.0	1
140	Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs. <i>Journal of Gastroenterology</i> , 2021, 56, 1008-1021.	2.3	3
141	Hepatitis B Virus Drug Resistance. , 2017, , 1227-1242.		10
142	Suppression of HBV by Tenofovir in HBV/HIV Coinfected Patients: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e68152.	1.1	75
143	The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs. <i>Journal of Clinical and Translational Hepatology</i> , 2014, 2, 202-11.	0.7	20
144	KASL Clinical Practice Guidelines: Management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2012, 18, 109.	4.5	143
145	Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 195.	4.5	27
146	Effi cacies of $\beta$ -L-D4A against Hepatitis B virus in 2.2.15 cells. <i>World Journal of Gastroenterology</i> , 2008, 14, 1263.	1.4	8

#	ARTICLE	IF	CITATIONS
147	Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. <i>World Journal of Gastroenterology</i> , 2010, 16, 2468.	1.4	14
148	Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment. <i>World Journal of Gastroenterology</i> , 2012, 18, 6437.	1.4	5
149	Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. <i>World Journal of Gastroenterology</i> , 2012, 18, 6996.	1.4	26
150	Management of antiviral drug resistance in chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2014, 20, 11641.	1.4	21
151	Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates. <i>World Journal of Gastroenterology</i> , 2014, 20, 17100.	1.4	2
152	Construction of a replication-competent hepatitis B virus vector carrying secreted luciferase transgene and establishment of new hepatitis B virus replication and expression cell lines. <i>World Journal of Gastroenterology</i> , 2019, 25, 5961-5972.	1.4	3
153	Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 32.	0.7	19
154	Antiviral efficacy of entecavir versus entecavir plus adefovir for hepatitis B virus rtA181V/T mutants alone. <i>Saudi Journal of Gastroenterology</i> , 2016, 22, 37.	0.5	5
155	Efficacy and Safety of Tenofovir-Based Rescue Therapy for Chronic Hepatitis B Patients with Previous Nucleo(s/t)ide Treatment Failure. <i>Gut and Liver</i> , 2014, 8, 64-69.	1.4	13
156	Effect and mechanism of $\hat{I}^2$ -L-D4A on DNA polymerase $\hat{I}\pm$ . <i>World Journal of Gastroenterology</i> , 2007, 13, 6243.	1.4	0
157	Adefovir plus lamivudine combination therapy in lamivudine-resistant chronic hepatitis B. <i>The Korean Journal of Hepatology</i> , 2008, 14, 235.	1.5	0
158	Treatment of Hepatitis B in HIV-Infected Persons. , 2012, , 141-149.		0
159	Is tenofovir disoproxil fumarate an all-powerful weapon in the treatment of chronic hepatitis B?. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 23.	0.7	1
160	Mechanisms of Resistance to Antiviral Agents. , 0, , 1894-1912.		3
161	Entecavir Resistance at rtS202, rtM250 May Cause Poor Viral Response to Tenofovir-based Rescue Therapy in Chronic Hepatitis B. <i>Korean Journal of Medicine</i> , 2015, 89, 527-536.	0.1	0
162	Efficacy and Safety of Tenofovir Disoproxil Fumarate for Patients with Lamivudine-Resistant Hepatitis B Virus Infection. <i>Journal of Gastroenterology and Hepatology Research</i> , 2016, 5, 2180-2184.	0.2	0
163	Treatment of Hepatitis B. , 2018, , 485-500.e5.		0
164	Article Commentary: Can Antiviral Therapy for Chronic Hepatitis B Enhance the Progression to Hepatocellular Carcinoma?. <i>Antiviral Therapy</i> , 2009, 14, 139-142.	0.6	10

#	ARTICLE	IF	CITATIONS
165	Zirconium Molybdate Nanocompositesâ€™ Sensing Platform for the Sensitive and Selective Electrochemical Detection of Adefovir. <i>Molecules</i> , 2022, 27, 6022.	1.7	1
166	Active site polymerase inhibitor nucleotides (ASPINs): Potential agents for chronic HBV cure regimens. <i>Antiviral Chemistry and Chemotherapy</i> , 2022, 30, 204020662211387.	0.3	2
167	Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2023, 67, .	1.4	4